Jasper Therapeutics Inc

Jasper Therapeutics is a clinical-stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Following its July 2026 acquisition of Kira Pharmaceuticals, the combined company is advancing a pipeline of three clinical-stage assets: KP-104 (Vensobafusp alfa), a bifunctional biologic targeting both the alternative and terminal complement pathways for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders; briquilimab, an anti-KIT antibody with broad therapeutic utility across transplant and immunologic indications including conditioning for stem cell transplant and mast cell-mediated diseases such as chronic urticarias and allergic asthma; and KP-701, a dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders. The company is pre-revenue and trades on Nasdaq under the ticker JSPR. Updated Aug 14, 2026